Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Truscreen GroupASX:TRU 3-Year EBITDA Growth Rate is 24.60% as of Mar. 2026, which is 170% above its 10-year median of 9.10. The stock has 4 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Truscreen Group ranks better than 71.35% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 24.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 24.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 11.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Truscreen Group was 42.50% per year. The lowest was -76.50% per year. And the median was 9.10% per year.
Truscreen Group (ASX:TRU) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Truscreen Group 3-Year EBITDA Growth Rate Related Terms
ASX:TRU vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Truscreen Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Truscreen Group 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Truscreen Group's 3-Year EBITDA Growth Rate falls into.
Truscreen Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 24.60% mean?
Truscreen Group (ASX:TRU) has a 3-Year EBITDA Growth Rate of 24.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Truscreen Group and its competitors. This is 170% above median its historical median of 9.10. According to the industry distribution chart, Truscreen Group ranks #198 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 28.7%.
Is Truscreen Group's 3-Year EBITDA Growth Rate too high?
Truscreen Group's current 3-Year EBITDA Growth Rate of 24.60% is 170% above median its 10-year median of 9.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.70. Truscreen Group's value of 24.60% is 219.5% above this industry median. Based on the distribution chart, Truscreen Group ranks #198 out of 691 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Truscreen Group's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Truscreen Group ranks #198 out of 691 companies for 3-Year EBITDA Growth Rate. This puts Truscreen Group in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.70. Truscreen Group's value of 24.60% is 219.5% above this benchmark. While the company's 10-year median is 9.10 vs. the industry median of 7.70, Truscreen Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.70, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Truscreen Group's current 3-Year EBITDA Growth Rate of 24.60% is 219.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Truscreen Group and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Truscreen Group's current 3-Year EBITDA Growth Rate is 24.60%, which is 170% above median its own 10-year median of 9.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Truscreen Group stock overvalued right now?
Based on GuruFocus' analysis, Truscreen Group (ASX:TRU) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 20% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 24.60%, which is 170% above median its 10-year median of 9.10 and 219.5% above the Medical Devices & Instruments industry median of 7.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Truscreen Group (ASX:TRU), the current 3-Year EBITDA Growth Rate is 24.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening device, which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRU has been successfully added to your 
